Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of allergic rhinitis~* In good health, determined by no clinically significant findings from medical history, 12-lead ECG, and vital signs~* Males or females who are surgically sterilized, post menopausal for the past year, or are using two acceptable methods of contraception against pregnancy through at least 6 months after the dose of study drug~Exclusion Criteria:~* History or clinical manifestations of significant metabolic, hepatic, renal, hematologic, immunodeficiency, pulmonary, cardiovascular, gastrointestinal, urologic, neurologic, or psychiatric disorders~* History of anaphylaxis, hypersensitivity or drug allergies~* Use of a non-biologic investigational drug or participation in an investigational study with a non-biologic drug within 30 days prior to dosing~* Use of a biologic investigational therapy or participation in an investigational study involving biologic therapy within 3 months prior to dosing~* Positive blood test for chronic viral infections by: hepatitis B surface antigen, hepatitis C virus antibody, or HIV antibody

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: EXPERIMENTAL): None
- C (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).